Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
27
APDN Quote, Financials, Valuation and Earnings
Last price:
$5.30
Seasonality move
:
-1.56%
Day range:
$4.88 - $5.16
52-week range:
$4.37 - $2,655.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.06x
P/B ratio:
0.25x
Volume:
61.9K
Avg. volume:
154.7K
1-year change:
-98.48%
Market cap:
$2.6M
Revenue:
$3.4M
EPS (TTM):
-$537.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
$1.3M | -$37.50 | 27.47% | -98.87% | -- |
|
FONR
Fonar
|
-- | -- | -- | -- | -- |
|
IMDX
Insight Molecular Diagnostics
|
$292K | -$0.24 | 180.72% | -33.33% | -- |
|
PRPH
ProPhase Labs
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
VCYT
Veracyte
|
$120.9M | $0.30 | 6.44% | 332.6% | $40.33 |
|
XWEL
XWELL
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
$5.03 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
FONR
Fonar
|
$16.09 | -- | $101.3M | 12.87x | $0.00 | 0% | 0.99x |
|
IMDX
Insight Molecular Diagnostics
|
$2.83 | -- | $80.9M | -- | $0.00 | 0% | 12.83x |
|
PRPH
ProPhase Labs
|
$0.37 | $13.80 | $15.5M | -- | $0.00 | 0% | 2.02x |
|
VCYT
Veracyte
|
$25.17 | $40.33 | $2B | 61.39x | $0.00 | 0% | 4.30x |
|
XWEL
XWELL
|
$1.02 | -- | $5.4M | -- | $0.00 | 0% | 0.15x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
-- | 5.076 | -- | 3.97x |
|
FONR
Fonar
|
-- | 1.699 | -- | 9.69x |
|
IMDX
Insight Molecular Diagnostics
|
-- | -1.933 | -- | 3.57x |
|
PRPH
ProPhase Labs
|
22.08% | -3.124 | 25.51% | 0.84x |
|
VCYT
Veracyte
|
-- | 2.266 | -- | 4.54x |
|
XWEL
XWELL
|
-- | 0.204 | -- | 1.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APDN
Applied DNA Sciences
|
$370.9K | -$3.5M | -84.02% | -84.02% | -352.03% | -$3.4M |
|
FONR
Fonar
|
$12.1M | $3.7M | 5.32% | 5.33% | 15.23% | $2.5M |
|
IMDX
Insight Molecular Diagnostics
|
$1.3M | -$5.9M | -693.81% | -693.81% | -310.66% | -$6.2M |
|
PRPH
ProPhase Labs
|
$526K | -$3.7M | -101.67% | -144.22% | -289.24% | -$3.4M |
|
VCYT
Veracyte
|
$79.5M | $1.2M | 2.85% | 2.85% | 1.02% | $3.5M |
|
XWEL
XWELL
|
$1.3M | -$3.2M | -153.74% | -153.74% | -64.9% | -$4.6M |
Applied DNA Sciences vs. Competitors
-
Which has Higher Returns APDN or FONR?
Fonar has a net margin of -336% compared to Applied DNA Sciences's net margin of 9.23%. Applied DNA Sciences's return on equity of -84.02% beat Fonar's return on equity of 5.33%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences37.71% -$230.25 $10.2M FONRFonar44.52% $0.37 $160.3M -
What do Analysts Say About APDN or FONR?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 447215.88%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Applied DNA Sciences has higher upside potential than Fonar, analysts believe Applied DNA Sciences is more attractive than Fonar.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 FONRFonar0 0 0 -
Is APDN or FONR More Risky?
Applied DNA Sciences has a beta of 0.068, which suggesting that the stock is 93.226% less volatile than S&P 500. In comparison Fonar has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.238%.
-
Which is a Better Dividend Stock APDN or FONR?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or FONR?
Applied DNA Sciences quarterly revenues are $983.4K, which are smaller than Fonar quarterly revenues of $27.2M. Applied DNA Sciences's net income of -$3.3M is lower than Fonar's net income of $2.5M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while Fonar's PE ratio is 12.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 0.99x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.06x -- $983.4K -$3.3M FONRFonar0.99x 12.87x $27.2M $2.5M
-
Which has Higher Returns APDN or IMDX?
Insight Molecular Diagnostics has a net margin of -336% compared to Applied DNA Sciences's net margin of -312.02%. Applied DNA Sciences's return on equity of -84.02% beat Insight Molecular Diagnostics's return on equity of -693.81%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences37.71% -$230.25 $10.2M IMDXInsight Molecular Diagnostics61.97% -$0.26 $10.2M -
What do Analysts Say About APDN or IMDX?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 447215.88%. On the other hand Insight Molecular Diagnostics has an analysts' consensus of -- which suggests that it could grow by 91.4%. Given that Applied DNA Sciences has higher upside potential than Insight Molecular Diagnostics, analysts believe Applied DNA Sciences is more attractive than Insight Molecular Diagnostics.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 IMDXInsight Molecular Diagnostics0 0 0 -
Is APDN or IMDX More Risky?
Applied DNA Sciences has a beta of 0.068, which suggesting that the stock is 93.226% less volatile than S&P 500. In comparison Insight Molecular Diagnostics has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.652%.
-
Which is a Better Dividend Stock APDN or IMDX?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. Insight Molecular Diagnostics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or IMDX?
Applied DNA Sciences quarterly revenues are $983.4K, which are smaller than Insight Molecular Diagnostics quarterly revenues of $2.1M. Applied DNA Sciences's net income of -$3.3M is higher than Insight Molecular Diagnostics's net income of -$6.7M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while Insight Molecular Diagnostics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 12.83x for Insight Molecular Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.06x -- $983.4K -$3.3M IMDXInsight Molecular Diagnostics12.83x -- $2.1M -$6.7M
-
Which has Higher Returns APDN or PRPH?
ProPhase Labs has a net margin of -336% compared to Applied DNA Sciences's net margin of -209.38%. Applied DNA Sciences's return on equity of -84.02% beat ProPhase Labs's return on equity of -144.22%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences37.71% -$230.25 $10.2M PRPHProPhase Labs36.76% $0.11 $19.4M -
What do Analysts Say About APDN or PRPH?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 447215.88%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3609.68%. Given that Applied DNA Sciences has higher upside potential than ProPhase Labs, analysts believe Applied DNA Sciences is more attractive than ProPhase Labs.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 PRPHProPhase Labs0 0 0 -
Is APDN or PRPH More Risky?
Applied DNA Sciences has a beta of 0.068, which suggesting that the stock is 93.226% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.412, suggesting its less volatile than the S&P 500 by 141.195%.
-
Which is a Better Dividend Stock APDN or PRPH?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or PRPH?
Applied DNA Sciences quarterly revenues are $983.4K, which are smaller than ProPhase Labs quarterly revenues of $1.4M. Applied DNA Sciences's net income of -$3.3M is lower than ProPhase Labs's net income of $4M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 2.02x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.06x -- $983.4K -$3.3M PRPHProPhase Labs2.02x -- $1.4M $4M
-
Which has Higher Returns APDN or VCYT?
Veracyte has a net margin of -336% compared to Applied DNA Sciences's net margin of 6.16%. Applied DNA Sciences's return on equity of -84.02% beat Veracyte's return on equity of 2.85%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences37.71% -$230.25 $10.2M VCYTVeracyte69.46% $0.09 $1.2B -
What do Analysts Say About APDN or VCYT?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 447215.88%. On the other hand Veracyte has an analysts' consensus of $40.33 which suggests that it could grow by 60.24%. Given that Applied DNA Sciences has higher upside potential than Veracyte, analysts believe Applied DNA Sciences is more attractive than Veracyte.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 VCYTVeracyte7 1 1 -
Is APDN or VCYT More Risky?
Applied DNA Sciences has a beta of 0.068, which suggesting that the stock is 93.226% less volatile than S&P 500. In comparison Veracyte has a beta of 2.071, suggesting its more volatile than the S&P 500 by 107.062%.
-
Which is a Better Dividend Stock APDN or VCYT?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or VCYT?
Applied DNA Sciences quarterly revenues are $983.4K, which are smaller than Veracyte quarterly revenues of $114.5M. Applied DNA Sciences's net income of -$3.3M is lower than Veracyte's net income of $7M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while Veracyte's PE ratio is 61.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 4.30x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.06x -- $983.4K -$3.3M VCYTVeracyte4.30x 61.39x $114.5M $7M
-
Which has Higher Returns APDN or XWEL?
XWELL has a net margin of -336% compared to Applied DNA Sciences's net margin of -67.19%. Applied DNA Sciences's return on equity of -84.02% beat XWELL's return on equity of -153.74%.
Company Gross Margin Earnings Per Share Invested Capital APDNApplied DNA Sciences37.71% -$230.25 $10.2M XWELXWELL18.78% -$1.00 $3.4M -
What do Analysts Say About APDN or XWEL?
Applied DNA Sciences has a consensus price target of --, signalling upside risk potential of 447215.88%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 586.28%. Given that Applied DNA Sciences has higher upside potential than XWELL, analysts believe Applied DNA Sciences is more attractive than XWELL.
Company Buy Ratings Hold Ratings Sell Ratings APDNApplied DNA Sciences0 1 0 XWELXWELL0 0 0 -
Is APDN or XWEL More Risky?
Applied DNA Sciences has a beta of 0.068, which suggesting that the stock is 93.226% less volatile than S&P 500. In comparison XWELL has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.424%.
-
Which is a Better Dividend Stock APDN or XWEL?
Applied DNA Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Applied DNA Sciences pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APDN or XWEL?
Applied DNA Sciences quarterly revenues are $983.4K, which are smaller than XWELL quarterly revenues of $7M. Applied DNA Sciences's net income of -$3.3M is higher than XWELL's net income of -$4.7M. Notably, Applied DNA Sciences's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Applied DNA Sciences is 0.06x versus 0.15x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APDNApplied DNA Sciences0.06x -- $983.4K -$3.3M XWELXWELL0.15x -- $7M -$4.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
